Tenet Healthcare Corporation (THC) jumps on deep earnings beat
Tenet Healthcare Corporation (THC) jumps after a sharp Q2 beat, but the real story is in the margins, segment mix, and raised outlook. This deep-dive breaks down USPI strength, hospital EBITDA gains, exchange revenue pressure, and why management’s higher 2026 guidance matters.
Tenet Healthcare Corporation (THC) delivered a powerful second-quarter beat, with adjusted EPS of $6.12 and revenue of $5.63 billion both topping estimates by a wide margin. The company also raised full-year 2026 guidance, signaling stronger operating momentum across hospitals and USPI and supporting the stock’s sharp post-earnings rally. For investors, the report points to improving margins, better cash generation, and a higher earnings run rate than the market expected.
Tenet Healthcare Corporation (THC) jumps 17.69% to $234.22 after a powerful second-quarter 2026 earnings beat and a higher full-year outlook. Adjusted EPS reached $6.12 versus the $4.26 estimate, while revenue came in at $5.63B against consensus of $5.43B.
Key Takeaways
THC reported adjusted EPS of $6.12 and revenue of $5.63B, beating estimates of $4.26 and $5.43B.
USPI produced $542M of adjusted EBITDA, with a 39% margin and 5% same-facility revenue growth.
Hospital adjusted EBITDA rose 22% year over year to $762M, producing an 18% margin despite a 17% decline in exchange revenue.
Tenet raised 2026 revenue guidance to $21.9B to $22.5B and adjusted EBITDA guidance to $4.83B to $5.03B.
Management expects adjusted free cash flow after NCI of $1.825B to $2.055B and more than $300M of 2026 ambulatory M&A spending.
Analyst consensus remains Buy, with 26 Buy ratings, six Holds, and zero Sell ratings. Post-earnings commentary focused on the broad operating beat and the guidance increase.
Financial Performance: A Beat Built on Margins and Volume
The central result in this THC earnings analysis is the scale of the adjusted EPS beat. Tenet delivered $6.12 per diluted share in the second quarter, compared with the $4.26 consensus estimate. The result also exceeded the $4.70 adjusted EPS reported in the first quarter of 2026 and the $4.02 reported in the second quarter of 2025.
Revenue reached $5.63B, above the $5.43B estimate and higher than $5.37B in the first quarter. The quarterly financial series lists revenue of $5.27B for the second quarter of 2025. Net income reached $830M in the latest quarter, compared with $700M in the first quarter and $370M in the fourth quarter of 2025.
The margin story matters more than the top-line beat. Consolidated adjusted EBITDA was $1.304B, equal to a 23.2% margin. Adjusted EBITDA grew 16.3% from the prior-year quarter, giving Tenet a stronger earnings conversion profile even as insurance enrollment shifted.
USPI, Tenet's ambulatory care platform, generated $542M of adjusted EBITDA and a 39% margin. Same-facility revenue grew 5%, while net revenue per case increased 6.3%. Same-facility case volume declined 1.2%, which management linked to its focus on higher-acuity procedures. Total joint replacement volume in ASCs grew 10% year over year.
Hospital Operations delivered $762M of adjusted EBITDA, up 22% from the second quarter of 2025. The segment posted an 18% adjusted EBITDA margin. Same-hospital inpatient adjusted admissions increased 2.6%, a sequential improvement from the first quarter, while revenue per adjusted admission rose 3.3%.
Exchange revenue remained the main pressure point. It fell 17% year over year and represented about 5.5% of consolidated net operating revenue. The headwind was partly offset by stronger commercial managed care revenue, higher-acuity services, and expense controls.
One notable line item was $92M of favorable out-of-period supplemental Medicaid revenue tied to prior years. Tenet recorded $70M of similar favorable revenue in the year-ago quarter. CFO Sun Park stressed that the company had not included this favorability in its initial 2026 guidance and still delivered a clean beat without the incremental Medicaid revenue.
The balance sheet also provided support. Tenet ended June with $2.1B of cash, no borrowings under its credit line, and no significant debt maturities until late 2027. The leverage ratio stood at 2.33 times EBITDA, or 2.9 times EBITDA less NCI.
Market Reaction and Analyst Response
The stock reaction was immediate and unusually large for a mature healthcare operator. After-hours trading sent THC up 17.6% to $234.03. The shares then showed a 14.6% pre-open gain the next morning before regular trading data placed the stock at $234.22, up 17.69%.
Trading volume reached 3,747,352 shares versus an average of 1,456,300. That combination of a sharp price move and elevated volume indicates that the market treated the quarter as a material reset in earnings power, rather than a routine estimate beat.
The main catalyst was the beat-and-raise combination. Tenet lifted adjusted EBITDA guidance by $295M at the midpoint, increased revenue guidance by $300M at the midpoint, and raised adjusted EPS guidance to $20.30 to $21.69 for 2026.
Analyst commentary emphasized two points. First, the performance was broad based across hospitals and USPI. Second, management tied the outlook increase to recurring operating improvements, including same-store revenue growth and expense management. The current analyst consensus is Buy, supported by 26 Buy ratings and six Holds.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Saumya Sutaria presented the quarter as evidence that Tenet's portfolio changes are working. His strategic message centered on higher-acuity care, local operating leadership, technology-enabled cost control, and growth in ambulatory surgery.
"We continue to deliver results exceeding our goals based on the fundamental performance of our business." - Saumya Sutaria, Chairman and CEO, Q2 2026 Earnings Call
Sutaria also framed the payer environment as difficult but manageable. Exchange enrollment and Medicaid uncertainty remain real risks, especially in Florida, Arizona, Michigan, South Carolina, and Texas. Still, the company is adjusting its cost base while protecting its focus on specialty services and higher-acuity procedures.
"Our consistent results are driven by a transformed portfolio of businesses, continued strategic focus on higher acuity specialty services, strong leadership at the local level and an ability to effectively manage through the current dynamic environment." - Saumya Sutaria, Chairman and CEO, Q2 2026 Earnings Call
CFO Sun Park supplied the numerical framework. USPI adjusted EBITDA guidance now stands at $2.16B to $2.22B. Hospital adjusted EBITDA guidance increased to $2.67B to $2.81B. Tenet also expects $140M from recently approved supplemental Medicaid increases, with about $20M expected in the second half.
"We remain committed to maintaining a deleveraged balance sheet and believe that we have significant financial flexibility to support our capital deployment priorities and continue to drive shareholder value." - Sun Park, Executive Vice President and CFO, Q2 2026 Earnings Call
Capital deployment will combine internal growth, acquisitions, and buybacks. Tenet repurchased 5.7 million shares for $1.04B in the second quarter and almost 7 million shares for $1.36B in the first half. The board added $2B to the repurchase authorization, while management expects 2026 ambulatory M&A spending to exceed $300M.
Analyst Q&A Highlights
The THC earnings call Q&A focused on three pressure points: exchange erosion, hospital revenue intensity, and ambulatory volume. Matthew Gilmore of KeyBanc asked whether the exchange decline matched expectations and whether patients were shifting into commercial coverage or uninsured care. Management said exchange revenue fell 17% and exchange admissions fell 13.5%, both roughly in line with expectations. Park added that the same market trends are expected through the third and fourth quarters.
"Exchange revenues have declined a significant 17% compared to second quarter of 2025." - Saumya Sutaria, Chairman and CEO, Q2 2026 Earnings Call
Stephen Baxter of Wells Fargo pressed management on the improvement in revenue per adjusted admission after a softer first quarter. The response defended the long-term acuity strategy but also acknowledged the effect of supplemental Medicaid revenue. The $92M prior-year Medicaid benefit helped the quarter, yet Park said Tenet's beat remained intact without it.
"We have not assumed any of this favorability in our initial guidance for 2026, and I would note that we had a clean beat in the quarter even without these incremental Medicaid revenues." - Sun Park, Executive Vice President and CFO, Q2 2026 Earnings Call
Pito Chickering of Deutsche Bank questioned the decline in ASC case volume and whether exchange dynamics were affecting the ambulatory platform. Management defended the shift toward higher-acuity procedures. Same-facility USPI revenue still grew 5%, net revenue per case rose 6.3%, and joint replacement volume increased 10%, giving the strategy measurable operating support.
"USPI is the premier ambulatory surgical asset in the space and the leading provider of low-cost, high-quality care that benefits all stakeholders across the health care ecosystem." - Saumya Sutaria, Chairman and CEO, Q2 2026 Earnings Call
Bottom Line
Tenet's second-quarter results combine a clear EPS and revenue beat with stronger margins, solid hospital demand, and continued USPI growth. The higher 2026 outlook and $2B buyback increase support the bullish case, although exchange revenue declines remain a concrete risk. For investors, the next phase of the THC story rests on whether Tenet can sustain its operating gains while funding ambulatory expansion without rebuilding leverage.
+Why did Tenet Healthcare stock jump after earnings?
Tenet Healthcare (THC) surged after reporting a major Q2 2026 earnings beat, with adjusted EPS of $6.12 versus the $4.26 estimate and revenue of $5.63 billion versus $5.43 billion expected. Management also raised full-year 2026 guidance, which reinforced the market’s view that earnings power is improving.
+Did Tenet Healthcare beat on both earnings and revenue in Q2 2026?
Yes, Tenet Healthcare beat on both metrics in Q2 2026. Adjusted EPS came in at $6.12, well above the $4.26 consensus, while revenue reached $5.63 billion versus the $5.43 billion estimate.
+What did Tenet Healthcare raise in its 2026 guidance?
Tenet raised 2026 revenue guidance to $21.9 billion to $22.5 billion and adjusted EBITDA guidance to $4.83 billion to $5.03 billion. It also lifted adjusted EPS guidance to $20.30 to $21.69 and expects adjusted free cash flow after NCI of $1.825 billion to $2.055 billion.
+How strong were Tenet Healthcare's hospital and USPI results?
USPI generated $542 million of adjusted EBITDA with a 39% margin and 5% same-facility revenue growth. Tenet's hospital operations produced $762 million of adjusted EBITDA, up 22% year over year, with an 18% margin.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on THC?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
